What is the OncoTherapy Science Inc. stock price forecast?

OncoTherapy Science Inc. is currently trading at ¥20. View real-time AI analysis on Alpha Lenz.

What is OncoTherapy Science Inc. insider trading activity?

View the latest insider trading data for OncoTherapy Science Inc. on Alpha Lenz.

What is OncoTherapy Science Inc.'s P/E ratio?

OncoTherapy Science Inc.'s P/E ratio is -6.1.

OncoTherapy Science Inc.

JPX · 4564

¥20+1(+5.26%)Market closed

Ask about OncoTherapy Science Inc.'s future dividend policy...

Alpha Chat Insight

“OncoTherapy Science Inc. trades at a P/E of -6.1 (undervalued) with modest ROE of -150.6%.”

Ask for details →

Company Overview

OncoTherapy Science Inc. is a biotechnology company primarily engaged in the research and development of therapies for cancer treatment. The company's core mission is to develop innovative medical solutions that target cancer at the molecular level, leveraging advanced genetic technologies and oncology research. OncoTherapy Science focuses on creating personalized cancer treatment options, including peptide-based and cell-based therapies, which aim to improve efficacy while reducing side effects. The company frequently collaborates with academic institutions and other biotechnology firms to enhance its research capabilities and expedite the development process. Operating in a critical sector, OncoTherapy Science plays a pivotal role in the pharmaceutical and healthcare industries, contributing to the advancement of specialized cancer treatments. Its work aligns with an increasing market demand for precision medicine and individualized therapy solutions, underscoring its significance in the global push towards improved oncology outcomes.

CEOMr. Junichi Shimada

Websitehttps://www.oncotherapy.co.jp

SectorHealthcare

IndustryBiotechnology

Employees47

Company Statistics

FY 2025

Profile

¥4,961,733,549Market Cap

¥750,048,000Revenue

0.00Shares Out

47Employees

Margins

-1.70%Gross

-108.51%EBITDA

-106.38%Operating

-108.41%Pre-Tax

-108.70%Net

Valuation

-6.09P/E

6.81P/B

6.62EV/Sales

-5.07EV/EBITDA

-6.09P/FCF

Growth (CAGR)

-13.37%Rev 3Yr

18.86%Rev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-80.62%ROA

-150.59%ROE

-80.29%ROIC

Financial Health

¥833,883,000Cash & Cash Equivalents

¥-407,792,000Net Debt

58.44%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“OncoTherapy Science Inc. trades at a P/E of -6.1 (undervalued) with modest ROE of -150.6%.”

Ask for details →

Frequently Asked Questions

OncoTherapy Science Inc. (ticker: 4564) is a company listed on JPX in the Healthcare sector (Biotechnology). It has approximately 47 employees. Market cap is $5.0B.

The current price is 20 with a P/E ratio of -6.09x and P/B of 6.81x.

ROE is -150.59% and operating margin is -106.38%. Annual revenue is $750M.